Leica Biosystems

Molecular Devices Appoints Mary Duseau as President, Bringing 25 Years of Experience in Life Sciences

Retrieved on: 
Wednesday, March 13, 2024
Health, Detection, Communication, PerkinElmer, Danaher Corporation, SAN, Leica Biosystems, University, Senior, Biology, Marketing, Molecular Devices, DHR, Pharmaceutical industry

SAN JOSE, Calif., March 13, 2024 /PRNewswire-PRWeb/ -- Molecular Devices, LLC., a leading high-performance life science solutions provider and an operating company in the life sciences segment of Danaher Corporation (NYSE:DHR), today announced Mary Duseau's appointment as its new president, succeeding interim president, Greg Milosevich.

Key Points: 
  • , a leading high-performance life science solutions provider and an operating company in the life sciences segment of Danaher Corporation (NYSE:DHR), today announced Mary Duseau's appointment as its new president, succeeding interim president, Greg Milosevich.
  • "Mary brings more than 25 years of life science experience and a track record of achieving exceptional business results to Molecular Devices," said Greg Milosevich, Vice President, and Group Executive Life Sciences Innovations Group at Danaher Corporation.
  • Prior to joining Molecular Devices, Mary spent six years at Leica Biosystems, also a Danaher operating company.
  • "In this short time as president, it's clear that Molecular Devices' innovative technology and diverse team are enabling a revolution of human health – and that's really inspiring," said Mary Duseau, President of Molecular Devices.

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution

Retrieved on: 
Tuesday, January 9, 2024
University, Patient, IEI, Research, DHR, Collection, Health, IDT, RNA, IGI, Science, Tissue, Nobel, Translation, Medicine, University of California, Berkeley, Government, Danaher Corporation, Beacon, Public, Safety, Quality control, FDA, Leica Biosystems, DSM-IV codes, Immunity, Engineering, Leica Microsystems, Brain, Hemophagocytic lymphohistiocytosis, Gene editing, Integrated DNA Technologies, HLH, Medical device

The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.

Key Points: 
  • The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.
  • The collaboration, which enables a substantial new research program at IGI, is the largest Danaher Beacon to date.
  • The Beacons program funds pioneering academic research with the goal of developing innovative technologies and applications for human health.
  • The unique nature of CRISPR makes it ideal for developing and deploying a platform capability for CRISPR cures on demand.

Exploring the Benefits of Parallel Multiplex Immunohistochemistry, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 2, 2023
Immunohistochemistry, R, Leica Biosystems, Research, Bachelor of Science, Telecommunications, Medical imaging

TORONTO, Oct. 2, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar delving into multiplex immunohistochemistry techniques and the importance of a modular approach in designing multiplex assays. Multiplex immunofluorescent (mxIF) and multiplex immunochromogenic (mxIHC) histochemistry have become important techniques for immunohistochemistry and spatialomics research as they yield significantly greater information into the tissue as the contextual relationships between markers are conserved.

Key Points: 
  • In this free webinar, gain insights into UltraPlex multiplex immunohistochemistry and the importance of a modular approach in designing multiplex assays.
  • The featured speaker will discuss why a modular approach is important when designing multiplex assays.
  • TORONTO, Oct. 2, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar delving into multiplex immunohistochemistry techniques and the importance of a modular approach in designing multiplex assays.
  • Join this webinar to gain insights into UltraPlex multiplex immunohistochemistry and the importance of a modular approach in designing multiplex assays.

Digital Pathology Market size worth USD 1719.31 Million, Globally, by 2030 at 13.64% CAGR: Verified Market Research®

Retrieved on: 
Tuesday, September 26, 2023
Hamamatsu Photonics, Drug development, Ventana Medical Systems, Bank statement, Pathology, Cancer, Woman, Breast, Research, Prostate, USD, Lung, Stomach, Incidence, Geography, Prevalence, Growth, Digital, Leica Biosystems, Thyroid, Liver cancer, Medical imaging, Cryptocurrency, Application

JERSEY CITY, N.J., Sept. 26, 2023 /PRNewswire/ -- The Global Digital Pathology Market is projected to grow at a CAGR of 13.64% from 2022 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 628.54 Million in 2021 and is expected to reach USD 1719.31 Million by the end of the forecast period.

Key Points: 
  • Digital Pathology Market Opportunities and Challenges:
    Despite its promising growth, the Global Digital Pathology Market faces certain challenges.
  • Digital Pathology Market Key Players:
    Leading players in the Global Digital Pathology Market include 3DHISTECH, Hamamatsu Photonics, Leica Biosystems, Koninklijke Philips, Apollo Enterprise Imaging, XIFIN, Ventana Medical Systems, Visiopharm, Corista, and Huron Digital Pathology.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Digital Pathology Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Digital Pathology Market into Product, Application, End-User, And Geography.

Digital Pathology Market size worth USD 1719.31 Million, Globally, by 2030 at 13.64% CAGR: Verified Market Research®

Retrieved on: 
Tuesday, September 26, 2023
Hamamatsu Photonics, Drug development, Ventana Medical Systems, Bank statement, Pathology, Cancer, Woman, Breast, Research, Prostate, USD, Lung, Stomach, Incidence, Geography, Prevalence, Growth, Digital, Leica Biosystems, Thyroid, Liver cancer, Medical imaging, Cryptocurrency, Application

JERSEY CITY, N.J., Sept. 26, 2023 /PRNewswire/ -- The Global Digital Pathology Market is projected to grow at a CAGR of 13.64% from 2022 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 628.54 Million in 2021 and is expected to reach USD 1719.31 Million by the end of the forecast period.

Key Points: 
  • Digital Pathology Market Opportunities and Challenges:
    Despite its promising growth, the Global Digital Pathology Market faces certain challenges.
  • Digital Pathology Market Key Players:
    Leading players in the Global Digital Pathology Market include 3DHISTECH, Hamamatsu Photonics, Leica Biosystems, Koninklijke Philips, Apollo Enterprise Imaging, XIFIN, Ventana Medical Systems, Visiopharm, Corista, and Huron Digital Pathology.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Digital Pathology Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Digital Pathology Market into Product, Application, End-User, And Geography.

Multiplex Immunohistochemistry Assays: Exploring Applications & Advantages, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, August 31, 2023
IHC, Fluorescence, Tissue, R, Leica Biosystems, Research, Laboratory, Antibody, EDT, Immunohistochemistry, Bachelor of Science, Medical imaging

TORONTO, Aug. 31, 2023 /PRNewswire-PRWeb/ -- Immunohistochemistry (IHC) is an indispensable tool for research laboratories by providing spatial context and phenotypic data. Multiplex immunohistochemistry technologies are in the early stages of disrupting legacy assays and revealing previously unknown relationships in all types of tissues.

Key Points: 
  • In this free webinar, understand the advantages of using fluorescence versus brightfield immunohistochemistry (IHC) in your research projects and learn how to utilize the data produced from multiplex immunohistochemistry assays.
  • The featured speaker will discuss appropriate antibodies to use in a multiplex IHC assay, and more.
  • TORONTO, Aug. 31, 2023 /PRNewswire-PRWeb/ -- Immunohistochemistry (IHC) is an indispensable tool for research laboratories by providing spatial context and phenotypic data.
  • Multiplex immunohistochemistry technologies are in the early stages of disrupting legacy assays and revealing previously unknown relationships in all types of tissues.

Digital Pathology Insights -- A Practical Guide to Creating Digital Ready Slides, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, August 10, 2023
Diagnosis, Marketing strategy, Digital Solutions, Acquisition, Leica Biosystems, Workflow, Doctor of Philosophy, 3D printing, Medical imaging

TORONTO, Aug. 10, 2023 /PRNewswire-PRWeb/ -- The adoption of digital pathology is a multifaceted project involving many stakeholders across the pathology department. The impact on the laboratory is not isolated to simply installing a scanner but rather affects the whole workflow to generate optimized Digital Ready Slides.

Key Points: 
  • In this free webinar, gain insight into the laboratory considerations for the adoption of digital pathology, the key attributes of digital ready slides and the impact of tissue preparation steps on scan quality.
  • Attendees will be introduced to the appropriate steps to support change management to help promote engagement and a path to success.
  • TORONTO, Aug. 10, 2023 /PRNewswire-PRWeb/ -- The adoption of digital pathology is a multifaceted project involving many stakeholders across the pathology department.
  • Register for this webinar to gain insight into the laboratory considerations for the adoption of digital pathology, the key attributes of digital ready slides and the impact of tissue preparation steps on scan quality.

Histologics LLC, Announces Jannalee Johnson, Business Development Consultant for Gynecologic and Wound Care Expansion

Retrieved on: 
Friday, August 4, 2023
Business development, Club, Histology, Business, Woman, Negotiation, Marketing, Patient, Gynaecology, System, MPH, Leica Biosystems, Rookie, Biopsy, Pharmaceutical industry, Nursing, MD

ANAHEIM, Calif., Aug. 4, 2023 /PRNewswire/ -- Histologics, LLC., a leader in the diagnostic field of tissue sampling, proudly welcomes Jannalee Johnson as their new Business Development Consultant for Gynecologic and Wound Care, effective Monday, July 24th, 2023.  With a remarkable track record spanning over 15 years in the laboratory industry, Ms. Johnson brings a wealth of experience and expertise to further strengthen Histologics' position as a premier innovator in the diagnostic, gynecologic, and wound care sectors.  Ms. Johnson's impressive career journey includes holding the position of Vice President of Sales at a prominent national women's health laboratory.  During her tenure, she played a pivotal role in negotiating an exclusive contract for a biopsy device solely for the company to market in the North America and United Kingdom, expanded the company's market reach and establishing key strategic partnerships. Most recently she held the position of Senior Product Manager and Marketing Manager at XiFin, Inc., exemplifying her ability to develop innovative solutions tailored to meet the evolving needs of healthcare professionals and patients.

Key Points: 
  • ANAHEIM, Calif., Aug. 4, 2023 /PRNewswire/ -- Histologics, LLC., a leader in the diagnostic field of tissue sampling, proudly welcomes Jannalee Johnson as their new Business Development Consultant for Gynecologic and Wound Care , effective Monday, July 24th, 2023.
  • "Her extensive experience in the laboratory and healthcare industry, coupled with her remarkable achievements, makes her the perfect fit to lead our Business Development efforts in the Gynecologic and Wound Care segments.
  • We are confident that under her guidance, we will continue to grow our worldwide footprint in our gynecologic and wound care divisions."
  • In her new role, Ms. Johnson will be responsible for fostering strategic partnerships, identifying business opportunities, and driving growth in the Gynecologic and Wound Care sectors worldwide.

HNL Lab Medicine Announces Groundbreaking Digital Pathology Investment

Retrieved on: 
Tuesday, July 18, 2023
Marie Cassidy, Pathology, Patient, Medicine, Diagnosis, Hospital Insurance and Diagnostic Services Act, Leica, Health, Leica Biosystems, Medical imaging

HNL Lab Medicine has selected solutions from Proscia , a digital pathology software company, and Leica Biosystems, a manufacturer of high-quality imaging hardware, to establish an advanced digital pathology practice.

Key Points: 
  • HNL Lab Medicine has selected solutions from Proscia , a digital pathology software company, and Leica Biosystems, a manufacturer of high-quality imaging hardware, to establish an advanced digital pathology practice.
  • These two companies will allow us to transform into a digital practice, enabling HNL Lab Medicine to deliver on the promise of precision medicine to improve patient care,” said Dr. Jordan Olson, Medical Director of HNL Lab Medicine.
  • "Beyond helping to drive quality and efficiency gains, HNL Lab Medicine lays the foundation for capitalizing on the full potential of this data with its digital pathology initiative.”
    The substantial investment in digital pathology is part of HNL Lab Medicine’s ongoing commitment to harnessing advanced technologies to improve patient outcomes.
  • By embracing digital innovation initiatives like digital pathology, HNL Lab Medicine aims to provide superior diagnostic services.

Leica Biosystems Strengthens Portfolio with FDA Clearance of Class II Mismatch Repair (MMR) Panel

Retrieved on: 
Monday, April 3, 2023
US Foods, MMR, CRC, Hereditary nonpolyposis colorectal cancer, Cancer, Large intestine, Antibody, Cancer Diagnostic Probe, IHC, Colorectal cancer, Acquisition, Patient, Laboratory, BOND, Workload, FDA, Leica Biosystems, Food, Vaccine

NEWCASTLE, United Kingdom, April 3, 2023 /PRNewswire/ -- Leica Biosystems today announced the US Food and Drug Administration (FDA) 510(k) clearance of the BOND MMR Antibody Panel, providing customers with a high-performing IHC Mismatch Repair (MMR) option when screening colorectal cancer patients for the identification of probable Lynch syndrome.

Key Points: 
  • NEWCASTLE, United Kingdom, April 3, 2023 /PRNewswire/ -- Leica Biosystems today announced the US Food and Drug Administration (FDA) 510(k) clearance of the BOND MMR Antibody Panel, providing customers with a high-performing IHC Mismatch Repair (MMR) option when screening colorectal cancer patients for the identification of probable Lynch syndrome.
  • "Pathologists can utilize the Leica Biosystems BOND MMR Antibody Panel on the BOND-III for clear, accurate assessment of mismatch repair protein status in only 2.5 hours," said Dr. Robert Monroe, Chief Medical Officer at Leica Biosystems.
  • Leica Biosystems has more than 20 years of experience developing and manufacturing IHC stains at its Newcastle, UK facility.
  • The BOND MMR Antibody Panel with 510(k) clearance is the company's latest offering.